| Species |
Human |
| Protein Construction |
| His |
IGFBP-7 (Ser27-Leu282)
Accession # Q16270 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IGFBP-7, His, Human at 5μg/ml (100μl/well) on the plate can bind Human CD93, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
27.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 35-40 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IGFBP-7, also known as Mac25/Angiomodulin (AGM), GFBP-rp1, tumor-derived adhesion factor (TAF) and prostacyclin-stimulating factor (PSF), is a secreted protein that contains three protein domain modules. Human IGFBP-rp1 cDNA encodes 282 amino acid (aa) residue precursor protein with a putative 26 aa signal peptide. IGFBP-7 binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion. |
| Synonyms |
IGFBP-7; IBP7; AGM; FSTL2; IGFBP-7v; IGFBPRP1; MAC25; PSF; RAMSVPS; TAF |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
